美金刚改善帕金森病认知功能和运动障碍的疗效分析

目的 本研究旨在探讨美金刚对帕金森病认知功能障碍和运动功能改善的临床疗效.方法 选取河南省人民医院门诊2007年3月至2010年3月间确诊的55例帕金森病痴呆患者,随机分为治疗组28例和对照组27例.治疗组采用帕金森病基本药物治疗加美金刚20 mg/d治疗;对照组仅采用帕金森病基本药物基本治疗.在治疗前和治疗后12、24周后分别对两组患者进行疗效评估.主要评估指标包括简易精神状态量表(MMSE)、阿尔茨海默病评价量表-认知分量表(ADAS-cog)、统一帕金森病评分量表第三部分运动评分(UPDRS-Ⅲ)及帕金森病的分期Hoehn & Yahr(H&Y,修正)分级量表.结果 在24周后治疗组患者量表评分MMSE(22.8±1.8),ADAS-cog(18.6±2.3)和UPDRS-Ⅲ(34.6±4.2)较对照组MMSE(18.5±1.7),ADAS-cog(21.9±2.4)和UPDRS-Ⅲ(41.2±4.0)均有明显改善(P＜0.05),且治疗组上述评分显著优于对照组(P＜0.05).结论 美金刚能有效地改善帕金森患者的认知功能障碍和运动障碍,且用药安全,耐受性好.

Abstract：

Objective To study the effects of memantine on cognitive and motor impairment in patients with Parkinson's disease (PD). Methods A total of 55 PD patients omplicated by varying degrees of cognitive impairment were randomly divided into two groups. The patients of experimental group ( n = 28 )received memantine (20 mg/d) while those in the control group (n = 27 ) conventional antiparkinsonian drug therapy alone. The cognitive and motor evaluations were assessed at pre-treatment and 12, 24 weeks posttreatment by clinical assessment, rating scales and neuropsychological tests. Results At week 24 the patients m the memantine group had better MMSE (22.8 ±1.8), ADAS-cog (18.6 ±2.3), and UPDRS-Ⅲ (34.6 ±4.2) scales scores than those taking placebo MMSE (18.5 ±1.7), ADAS-cog (21.9 ±2.4), and UPDRS-Ⅲ (41.2 ±4.0). Patients treated with memantine had better improvement on the MMSE (P ＜ 0.05), ADAScog (P＜ 0.05), and UPDRS-Ⅲ (P＜ 0.05) scales compared with the control group by the end of study week 24. Conclusion Memantine may improve the cognitive and motor impairments of PD. And it is both safe and well-tolerated.

Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease

Objective To study the effects of memantine on cognitive and motor impairment in patients with Parkinson's disease (PD). Methods A total of 55 PD patients omplicated by varying degrees of cognitive impairment were randomly divided into two groups. The patients of experimental group ( n = 28 )received memantine (20 mg/d) while those in the control group (n = 27 ) conventional antiparkinsonian drug therapy alone. The cognitive and motor evaluations were assessed at pre-treatment and 12, 24 weeks posttreatment by clinical assessment, rating scales and neuropsychological tests. Results At week 24 the patients m the memantine group had better MMSE (22.8 ±1.8), ADAS-cog (18.6 ±2.3), and UPDRS-Ⅲ (34.6 ±4.2) scales scores than those taking placebo MMSE (18.5 ±1.7), ADAS-cog (21.9 ±2.4), and UPDRS-Ⅲ (41.2 ±4.0). Patients treated with memantine had better improvement on the MMSE (P ＜ 0.05), ADAScog (P＜ 0.05), and UPDRS-Ⅲ (P＜ 0.05) scales compared with the control group by the end of study week 24. Conclusion Memantine may improve the cognitive and motor impairments of PD. And it is both safe and well-tolerated.